PEPentwater Capital Management LP
Institutional investor · Portfolio as of Q2 2019
Top Holdings181 positions
| 6.4M | $1.9B | 20.3% | — | — | — | Increased — | |
ANADARKO PETE CORP | 8.8M | $619.5M | 6.7% | — | — | 1 qtr | New 97 |
ALLERGAN PLC | 3.6M | $598.7M | 6.4% | — | — | 2 qtrssince 2019-Q1 | Increased 99 |
CELGENE CORP | 5.8M | $531.9M | 5.7% | — | — | 2 qtrssince 2019-Q1 | Decreased 0 |
RED HAT INC | 2.4M | $457.1M | 4.9% | — | — | 2 qtrssince 2019-Q1 | Increased 75 |
| 3.2M | $291.6M | 3.1% | — | — | — | Decreased — | |
ZAYO GROUP HLDGS INC | 8.2M | $268.2M | 2.9% | — | — | 2 qtrssince 2019-Q1 | Increased 85 |
CYPRESS SEMICONDUCTOR CORP | 10.2M | $227.3M | 2.4% | — | — | 1 qtr | New 79 |
TURQUOISE HILL RESOURCES LTD | 181.9M | $225.6M | 2.4% | — | — | 2 qtrssince 2019-Q1 | Decreased 0 |
MELLANOX TECHNOLOGIES LTD | 2M | $219.8M | 2.4% | — | — | 2 qtrssince 2019-Q1 | Increased 65 |
NXP SEMICONDUCTORS N V | 2.2M | $218.7M | 2.4% | $79.22 | +10.73% | 2 qtrssince 2019-Q1 | Decreased 0 |
| 2.1M | $207.4M | 2.2% | — | — | — | Increased — | |
| 1.2M | $185.1M | 2.0% | — | — | — | Decreased — | |
| 1.5M | $166M | 1.8% | — | — | — | Increased — | |
| 3.1M | $157.4M | 1.7% | — | — | — | New — | |
| 2.8M | $128.1M | 1.4% | — | — | 1 qtr | New 69 | |
WELLCARE HEALTH PLANS INC | 400,900 | $114.3M | 1.2% | — | — | 2 qtrssince 2019-Q1 | Decreased 0 |
ESPERION THERAPEUTICS INC NE | 2.4M | $113.3M | 1.2% | $40.15 | +15.87% | 2 qtrssince 2019-Q1 | Decreased 0 |
| 599,600 | $112M | 1.2% | — | — | — | New — | |
| 390,000 | $111.2M | 1.2% | — | — | — | Increased — |
Pentwater Capital Management LP manages $9.3B across 181 positions as of Q2 2019. Top holdings: SPDR S&P 500 ETF TR puts (20.3%), APC (6.7%), AGN (6.4%). Fund DNA: Momentum Trader. HoldingsIntel Score: 1.5/5.0.
Active quarter - 54 new positions, 35 exits, 17 increased. Top move: AGN (INCREASED, conviction 99). Portfolio: $9.3B across 181 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR